Artykuł w czasopiśmie
Brak miniatury
Licencja

CC-BY-NC-SACC-BY-NC-SA - Uznanie autorstwa - Użycie niekomercyjne - Na tych samych warunkach

Novel podophyllotoxin and benzothiazole derivative induces transitional morphological and functional changes in HaCaT cells

Autor
Strus, Piotr
Szczepankiewicz, Andrzej
Wojcik, Cezary
Borensztejn, Karol
Lisiecki, Kamil
Bialy, Lukasz P.
Mlynarczuk-Bialy, Izabela
NIEZNAŃSKA, HANNA
Czarnocki, Zbigniew
Data publikacji
2021
Abstrakt (EN)

Podophyllotoxin (PPT) is an antimitotic drug used topically in the treatment of anogenital warts. Due to its toxicity it cannot be administered systemically as an anticancer agent. However, modified PPT derivatives such as etoposide and teniposide are used clinically as systemic agents. Thus, we invented novel PPT derivative KL3 that was synthesized by photocyclization. Earlier we have shown that KL3 has an anticancer effect in various cell lines. Here we compared the toxicity of KL3 vs PPT on non-cancerous normal human keratinocytes (HaCaT) and peripheral blood mononuclear cells (PBMC) showing that KL3 is less toxic than PPT to non-cancerous cells. At concentrations that neither induced cell death, nor affected cell cycle, KL3 in HaCaT cells evoked transient ultrastructural features of ER stress, swelling of mitochondria and elongation of cytoplasmic processes. Those changes partially reversed with prolonged incubation while features of autophagy were induced. PPT in equivalent concentrations induced HaCaT cell death by cell cycle arrest, intrinsic apoptosis and finally disintegration of cell membranes followed by secondary necrosis. In conclusion, we show that the KL3 derivative of PPT in contrast to PPT allows repair of normal keratinocytes and triggers mechanisms that restore non-tumor cell homeostasis

Słowa kluczowe EN
Podophyllotoxin
Benzothiazole
Keratinocytes
Cell death
Apoptotic caspase 9
HaCaT ultrastructure in TEM
Dyscyplina PBN
nauki chemiczne
Czasopismo
Toxicology in Vitro
Tom
73
Strony od-do
art.no. 105144
ISSN
0887-2333
Data udostępnienia w otwartym dostępie
2021-03-12
Licencja otwartego dostępu
Uznanie autorstwa- Użycie niekomercyjne- Na tych samych warunkach